Posted on September 5th, 2016 by
The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence.” These updates were recently published in the Journal of Clinical Oncology.
The majority of breast cancers are referred to as HR-positive, meaning their cancer is stimulated to grow from exposure to the female hormones estrogen and/or progesterone. These patients are treated with endocrine therapy (sometimes referred to as hormone, or anti-estrogen therapy), which reduces the cancer cells’ exposure to estrogen through varying mechanisms. Endocrine therapy has proven extremely effective in reducing HR-positive cancer growth and spread for extended periods of time.
Metastatic breast cancer refers to cancer that originated in the breast, but has spread to several and/or distant sites in the body. The goals of treatment for metastatic breast cancer are to improve duration of survival while maintaining quality of life.
The recommendations set forth by the recent convening of the Expert Panel specifically for women with HR-positive, metastatic breast cancer included the following:
For the ASCO publication regarding newly set forth recommendations specifically for HR-positive, metastatic breast cancer, go to: http://jco.ascopubs.org/content/34/25/3069.abstract?jco-home for the abstract, and http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer#/11751 for a more complete review.
Reference: Rugo H, Rumble R, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology. 2016; 34 (25): 3069-3103. doi:10.1200/JCO.2016.67.1487JCO.
Copyright © 2017 CancerConnect. All Rights Reserved.
You must be logged-in to the site to post a comment.
Page loaded in 0.440 seconds